Doxazosin arm of the allhat study discontinued: How equal are antihypertensive drugs?

Current Hypertension Reports

Volumn 2, Issue 3, 2000, Pages 241-242

  Messerli, Franz H ^a   Grossman, Ehud ^b  

^a OCHSNER MEDICAL CENTER   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG EFFECT; HEART INFARCTION; HUMAN; RISK FACTOR;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; CORONARY DISEASE; DIURETICS; DOXAZOSIN; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 0034203731     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-000-0005-3     Document Type: Review

References (16)

1. Elliott WJ: ALLHAT: the largest and most important clinical trial in hypertension ever done in the USA. Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial. Am J Hypertens 1996, 9: 409-411.
2. Collins R, Peto R, MacMahon S, et al.: Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990, 335: 827-838.
3. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angio-tensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353: 611-616.
4. Hansson L, Lindholm LH, Ekbom T, et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354: 1751-1756.
5. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317: 713-720.
6. Giordano M, Matsuda M, Sanders L, et al.: Effects of angio-tensin- converting enzyme inhibitors, Ca2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes 1995, 44: 665-671.
7. Grimm RH Jr, Flack JM, Grandits GA, et al.: Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA 1996, 275: 1549-1556.
8. Kaplan NM: Alpha1-blockers. In The ABC's of Antihypertensive Therapy, edn 2. Edited by Messerli FH. New York: Authors' Publishing House; 2000: 99-110.
9. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970, 213: 1143-1152.
10. Messerli FH, Grossman E, Goldbourt U: Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998, 279: 1903-1907.
11. Staessen JA, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997, 350: 757-764.
12. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [see comments] [published erratum appears in Arch Intern Med 1998 23: 158:573]. Arch Intern Med 1997, 157: 2413-2446.
13. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999, 17: 151-183.
14. Ramsay LE, Williams B, Johnston GD, et al.: British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999, 319: 630-635.
15. Feldman RD: The 1999 Canadian recommendations for the management of hypertension. Can J Cardiol 1999, 15(G):57G-64G.
16. Plouin P-F, Bobrie G, Amouyel P, et al.: Diagnostic et traitment de l'hypertension arterielle essentielle de l'adulte de 20 à 80 ans. ANAES/Service des References Medicales 1997, September: 241-277.